Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -5250.17% as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
ODTX EBITDA Margin has fewer than three reported periods, so a trend chart would be misleading.
EBITDA MARGIN
-5250.17%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Odyssey Therapeutics, Inc.
Market Cap
$908.51M
EBITDA Margin
-5250.17%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$914.38M
EBITDA Margin
20.95%
TTM Avg
21.20%
3Y Avg
20.44%
5Y Avg
19.67%
Market Cap
$926.11M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$931.41M
EBITDA Margin
-64.07%
TTM Avg
-61.50%
3Y Avg
-81.15%
5Y Avg
-81.15%
Market Cap
$937.68M
EBITDA Margin
-448.41%
TTM Avg
-402.69%
3Y Avg
-402.69%
5Y Avg
-402.69%
Market Cap
$877.07M
EBITDA Margin
-189.51%
TTM Avg
-701.94%
3Y Avg
-497.69%
5Y Avg
-575.23%
Market Cap
$943.74M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$866.51M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $908.51M | -5250.17% | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $914.38M | 20.95% | 21.20% | 20.44% | 19.67% |
| Bioventus Inc. (BVS)vs › | $899.34M | 18.58% | 12.56% | -0.37% | 4.16% |
| MoonLake Immunotherapeutics (MLTX)vs › | $926.11M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $931.41M | -64.07% | -61.50% | -81.15% | -81.15% |
| Kura Oncology, Inc. (KURA)vs › | $937.68M | -448.41% | -402.69% | -402.69% | -402.69% |
| Arbutus Biopharma Corp (ABUS)vs › | $877.07M | -189.51% | -701.94% | -497.69% | -575.23% |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $943.74M | N/A | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $866.51M | N/A | N/A | N/A | N/A |
| Savara Inc. (SVRA)vs › | $950.86M | -19083.66% | -19083.66% | -19083.66% | -24221442.25% |
Gross Margin
100.0%
EBITDA Margin
-5250.2%
Operating Margin
-5415.2%
Net Margin
-4994.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -5250.17% |
